An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Molecular Imaging and Contrast Agent Database (MICAD) [Internet].
Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
Top results in this bookTable of Contents
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
StatPearls [Internet].
Treasure Island (FL): StatPearls Publishing; 2026 Jan-.
The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies [Internet]. 8th edition.
Sureda A, Corbacioglu S, Greco R, et al., editors.
Cham (CH): Springer; 2024.
LiverTox®: Clinical and Research Information on Drug-Induced Liver Injury [Internet].
Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
Talquetamab (Talvey): Therapeutic area: Relapsed or refractory multiple myeloma: Reimbursement Review [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2025 Jun.
Ciltacabtagene Autoleucel (Carvykti): CADTH Reimbursement Review: Therapeutic area: Relapsed or refractory multiple myeloma [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Aug.
Holland-Frei Cancer Medicine. 6th edition.
Kufe DW, Pollock RE, Weichselbaum RR, et al., editors.
Hamilton (ON): BC Decker; 2003.
The EBMT/EHA CAR-T Cell Handbook [Internet].
Kröger N, Gribben J, Chabannon C, et al., editors.
Cham (CH): Springer; 2022.
Drugs and Lactation Database (LactMed®) [Internet].
Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
Glofitamab (Columvi): Therapeutic area: Relapsed or refractory diffuse large B-cell lymphoma: Reimbursement Review [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2026 Mar.
Childhood Cancer and Functional Impacts Across the Care Continuum.
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Care Services; Committee on Childhood Cancers and Disability; Aiuppa L, Cartaxo T, Spicer CM, et al., editors.
Washington (DC): National Academies Press (US); 2020 Dec 9.
Elranatamab (Elrexfio): Therapeutic area: Relapsed or refractory multiple myeloma: Reimbursement Review [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Nov.
Ciltacabtagene Autoleucel (Carvykti): Indication: For the treatment of adult patients with multiple myeloma, who have received 1 to 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide: Reimbursement Recommendation [Internet].
Epcoritamab (Epkinly): Therapeutic area: Relapsed or refractory diffuse large B-cell lymphoma: Reimbursement Review [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Oct.
Glofitamab (Columvi): CADTH Reimbursement Review: Therapeutic area: Relapsed or refractory diffuse large B-cell lymphoma [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Apr.
Talquetamab (Talvey): Indication: For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on or after the last therapy: Reimbursement Recommendation [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2025 Mar.
Belantamab mafodotin (Blenrep), bortezomib, dexamethasone: Indication: Belantamab mafodotin is indicated in combination with bortezomib and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy: Reimbursement Recommendation [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2025 Oct.
Belantamab Mafodotin (Blenrep), Bortezomib, Dexamethasone: Therapeutic area: Previously treated multiple myeloma: Reimbursement Review [Internet].
Elranatamab (Elrexfio): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Jun.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on